LivaNova PLC (NASDAQ:LIVN) insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $112.83, for a total value of $169,245.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ LIVN opened at $116.29 on Friday. The firm has a market cap of $5.67 billion, a price-to-earnings ratio of 33.82, a P/E/G ratio of 3.42 and a beta of 0.95. The company has a current ratio of 1.51, a quick ratio of 1.08 and a debt-to-equity ratio of 0.03. LivaNova PLC has a fifty-two week low of $72.30 and a fifty-two week high of $131.54.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.04. The company had revenue of $287.50 million for the quarter, compared to analyst estimates of $278.08 million. LivaNova had a positive return on equity of 9.24% and a negative net margin of 4.93%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.93 earnings per share. Equities analysts anticipate that LivaNova PLC will post 3.18 EPS for the current year.
A number of analysts have recently issued reports on LIVN shares. ValuEngine raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 27th. Zacks Investment Research raised LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. BidaskClub lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 12th. Needham & Company LLC reissued a “buy” rating and set a $128.00 price objective on shares of LivaNova in a research note on Wednesday, July 18th. Finally, Stifel Nicolaus boosted their price objective on LivaNova from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, July 24th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $113.33.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
See Also: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.